BFC Planning’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
BFC Planning's CLDX Position: Q3 2026 in Review
BFC Planning held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 22 shares worth $713. The position accounts for ﹤0.01% of the portfolio, ranked #3235.
BFC Planning first reported a position in CLDX in Q3 2025 and has held it in 5 quarters since. The position peaked at $819 in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- BFC Planning held 22 shares of Celldex Therapeutics worth $713 as of Q3 2026.
- BFC Planning left its Celldex Therapeutics share count unchanged in Q3 2026.
- Celldex Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3235 holding.
- BFC Planning first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 5 quarters since.
- BFC Planning's Celldex Therapeutics position peaked at $819 in Q2 2026.
- 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.